HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC label disclaimer for nonconforming small packages suggested by NDAC.

This article was originally published in The Rose Sheet

Executive Summary

OTC LABEL 6-POINT TYPE SIZE MINIMUM STANDARD WITH FLEXIBILITY for smaller containers and packages recommended by FDA's Nonprescription Drugs Advisory Committee during a July 14 meeting on the agency's proposed rule on OTC label reform in Bethesda, Md. The eight voting members of the committee unanimously agreed that the agency should "attempt to use the 6-point [type size] as the standard and that any modification from that be evaluated to ensure readability is preserved." The motion was proposed by NDAC member Eric Brass, MD/PhD, Harbor-UCLA Medical Center.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS004423

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel